SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Lyke, K. E.; Atmar, R. L.; Dominguez Islas, C. P.; Posavad, C. M.; Szydlo, D.; PaulChourdhury, R.; Deming, M. E.; Eaton, A.; Jackson, L. A.; Branche, A. R.; El Sahly, H. M.; Rostad, C. A.; Martin, J. M.; Johnston, C.; Rupp, R. E.; Mulligan, M. J.; Brady, R. C.; Frenck, R. W.; Bäcker, M.; Kottkamp, A. C.; Babu, T. M.; Rajakumar, K.; Edupuganti, S.; Dobrzynski, D.; Coler, R. N.; Archer, J. I.; Crandon, S.; Zemanek, J. A.; Brown, E. R.; Neuzil, K. .M.; Stephens, D. S.; Post, D. J.; Nayak, S. U.; Roberts, P. C.; Beigel, J.; Montefiori, D.
Show abstract
As part of an ongoing study assessing homologous and heterologous booster vaccines, following primary EUA series, we assessed neutralization of D614G and Omicron variants prior to and 28 days after boost. Subset analysis was done in six combinations (N = 10/group): four homologous primary-booster combinations included mRNA-1273 two-dose priming followed by boosting with 100-g or 50-g mRNA-1273, Ad26.COV2.S single-dose priming followed by Ad26.COV2.S booster and BNT162b2 two-dose priming followed by BNT162b2 boosting; and two heterologous primary-booster combinations: BNT162b2 followed by Ad26.COV2.S and Ad26.COV2.S followed by BNT162b2. Neutralizing antibody (Nab) titers to D614G on the day of boost (baseline) were detected in 85-100% of participants, with geometric mean titers (GMT) of 71-343 in participants who received an mRNA vaccine series versus GMTs of 35-41 in participants primed with Ad26.OV2.S. Baseline NAb titers to Omicron were detected in 50-90% of participants who received an mRNA vaccine series (GMT range 12.8-24.5) versus 20-25% among participants primed with Ad26.COV2.S. The booster dose increased the neutralizing GMT in most combinations to above 1000 for D614G and above 250 for Omicron by Day 29. Homologous prime-boost Ad26.COV2.S had the lowest NAb on Day 29 (D614G GMT 128 and Omicron GMT 45). Results were similar between age groups. Most homologous and heterologous boost combinations examined will increase humoral immunity to the Omicron variant.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study 96%
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 96%
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 96%
Similar papers in this journal
- Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants 95%
- Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 95%
- BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 95%
Similar papers in this journal
- Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report 96%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 96%
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar 96%
Similar papers in this journal
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 97%
- Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting 96%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.